Childhood Bacterial Respiratory Diseases Past, Present, and Future

Pediatric Infectious Disease Journal

Volumn 28, Issue 10 SUPPL., 2009, Pages

  Nohynek, Hanna ^a   Madhi, Shabir ^b,c   Grijalva, Carlos G ^d  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b Respiratory and Meningeal Pathogens Research Unit   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute respiratory infections; Bacterial infections; Epidemiology; Incidence; Morbidity; Mortality; PCV; Pneumonia; Prevention; Vaccine

Indexed keywords

PENICILLIN G; PNEUMOCOCCUS VACCINE;

BACTERIAL PNEUMONIA; BORDETELLA PERTUSSIS; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; INFECTION RISK; MORBIDITY; OTITIS MEDIA; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 70350438001     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181b6d800     Document Type: Article

References (55)

1. Centres for Disease Control and Prevention (CDC). Achievements in Public Health, 1900-1999 Impact of Vaccines Universally Recommended for Children-United States, 1990-1998. Morb Mortal Wkly Rep. 1999;48:5.
2. 2. Madhi SA, Levine OS, Hajjeh R, et al. Vaccines to prevent pneumonia and improve child survival. Bull World Health Organ. 2008;86:365-372. (Pubitemid 351694317)
3. 3. Melegaro A, Edmunds WJ, Pebody R, et al. The current burden of pneumococcal disease in England and Wales. J Infect. 2006;52:37-48. (Pubitemid 43115506)
4. 4. Scott JA. The preventable burden of pneumococcal disease in the developing world. Vaccine. 2007;25:2398-2405. (Pubitemid 46366119)
5. 5. Wolf J, Daley AJ. Microbiological aspects of bacterial, lower respiratory tract illness in children: typical pathogens. Paediatr Respir Rev. 2007;8: 204-210; quiz 210-1201 (Pubitemid 47440672)
6. 6. Vuori-Holopainen E, Peltola H. Reappraisal of lung tap: review of an old method for better etiologic diagnosis of childhood pneumonia. Clin Infect Dis. 2001;32:715-726. (Pubitemid 32221929)
7. Peltola VT, McCullers JA. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis J. 2004;23:S87-S97.
8. 8. Farha T, Thomson AH. The burden, of pneumonia in children in the developed world. Paediatr Respir Rev. 2005;6:76-82. (Pubitemid 40692043)
9. WHO/UNICEF. Pneumonia: The Forgotten Killer of Children. New York, Geneva: WHO/UNICEF; 2006.
10. 10. Rudan I, Tomaskovic L, Boschi-Pinto C, et al. Global, estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Organ. 2004;82:895-903. (Pubitemid 40065157)
11. 11. Williams BG, Gouws E, Boschi-Pinto C, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2:25-32. (Pubitemid 36109303)
12. 12. Morris SS, Black RE, Tomaskovic L. Predicting the distribution of underfive deaths by cause in countries without adequate vital registration systems. Int J Epidemiol. 2003;32:1041-1051. (Pubitemid 38072693)
13. 13. Bryce J, Boschi-Pinto C, Shibuya K, et al. WHO estimates of the causes of death in children. Lancet. 2005;365:1147-1152. (Pubitemid 40417564)
14. WHO HIV drives children's pneumonia in sub Sanaran Africa. Bull World Health Organ. 2008;86:321-416.
15. WHO, UNICEF, the Hib initiative, PneumoADIP. Global Action Plan for the Prevention and Control of Pneumonia (GAPP). Geneva, Switzerland: WHO; 2007.
16. 16. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348:1747-1755. (Pubitemid 36514705)
17. Centres for Disease Control and Prevention (CDC). Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practice (ACIP). Morb Mortal Wkly Rep. 1997;46:1-24.
18. Musher DM, Rueda-Jaimes AM, Graviss EA, et al. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis. 2006;43: 1004-1008.
19. 19. Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis. 2003;3:71-78. (Pubitemid 36164202)
20. JC, Jackson M, Yu O, et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine. 2008;26:4947-4954.
21. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
22. a. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25:779-781.
23. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354:1455-1463.
24. 23. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746. (Pubitemid 36514704)
25. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis. 2006;6:303-312.
26. MacLeod CM. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med. 1945;82:445-465.
27. 26. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA. 1999;281:61-66. (Pubitemid 29025101)
28. Dowell SF, Kupronis BA, Zell ER, et al. Mortality from pneumonia in children in the United States, 1939 through 1996. N Engl J Med. 2000;342: 1399-1407.
29. McCracken GH Jr. Diagnosis and management of pneumonia in children. Pediatr Infect Dis J. 2000; 19:924-928.
30. Ong SB, Thong ML, Tay LK. Viruses and bacteria associated with acute respiratory illnesses in young children in general practice. Southeast Asian J Trop Med Public Health. 1978;9:98-102.
31. Bartlett JG. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy. Clin Infect Dis. 2008;47(suppl 3):S232-S236.
32. Sung RY, Chan PK, Tsen T, et al. Identification of viral and atypical bacterial pathogens in children hospitalized with acute respiratory infections in Hong Kong by multiplex PCR assays. J Med Virol. 2009; 81:153-159.
33. Overturf GD. American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics. 2000;106:367-376.
34. 33. Stenberg K, Johns B, Scherpbier RW, et al. A financial road map to scaling up essential child health interventions in 75 countries. Bull World Health Organ. 2007;85:305-314. (Pubitemid 46556730)
35. Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;86:408-416.
36. Gordon HS, Harper DL, Rosenthal GE. Racial variation in predicted and observed in-hospital death. A regional analysis. JAMA. 1996;276:1639-1644.
37. 36. Sazawal S, Black RE. Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of communitybased trials. Lancet Infect Dis. 2003;3:547-556. (Pubitemid 37064533)
38. 37. Jones G, Steketee RW, Black RE, et al. How many child deaths can we prevent this year? Lancet. 2003;362:65-71. (Pubitemid 36835825)
39. WHO. WHO Vaccine-Preventable Diseases: Monitoring System-2007 Global Summary. Geneva, Switzerland: World Health Organization; 2007.
40. Lob-Levyt J. Delivering the promise: through new markets, new money and new partnerships for development. Available at: http://www.gavialliance.org/ support/who/eligible/index.php and http://www.gavialliance.org/media-centre/ statements/2008-04-10-en-promise.php. Accessed on. 2008.
41. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1-35.
42. 41. Monto AS, Lehmann D. Acute respiratory infections (ARI) in children: prospects for prevention. Vaccine. 1998;16:1582-1588. (Pubitemid 28366096)
43. Kellner JD, Scheifele D, Vanderkooi OG, et al. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with streptococcus pneumoniae in children in Calgary, Canada. Pediatr Infect Dis J. 2008;27:526-532.
44. Garcia-Rodriguez JA, Fresnadillo Martinez MJ. Dynamics of nasopharyngeal colonization by potential respiratory pathogens. J Antimicrob Chemother. 2002;50(suppl S2):59-73.
45. 44. Käyhty H. Auranen K, Nohynek H, et al. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines. 2006;5:651-667. (Pubitemid 46021047)
46. Progress in introduction of pneumococcal conjugate vaccine-worldwide, 2000-2008. Morb Mortal Wkly Rep. 2008;57:1148-1151.
47. 46. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409. (Pubitemid 32128672)
48. Lucero MG, Dulalia VE, Parreno RN, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age. Cochrane Database Sys Rev. 2004;4:CD004977.
49. 48. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomized double-blind efficacy study. Lancet. 2006;367:740-748. (Pubitemid 43326292)
50. WHO. Detailed Review Paper on Pneumococcal Conjugate Vaccine-presented to the WHO Strategic Advisory Group of Experts (SAGE) on Immunization, November 2006. Geneva, Switzerland: WHO; 2007:1-69
51. 50. Zhou F, Kyaw MH, Shefer A, et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med. 2007;161:1162-1168. (Pubitemid 350223571)
52. Grijalva CG, Griffin MR. Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA. Expert Rev Vaccines. 2008;7:83-95.
53. de Roux A, Schmole-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46:1015-1023.
54. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295:1668-1674.
55. Cohen BJ, Parry RP, Andrews N, et al. Laboratory methods for assessing vaccine potency retained in aerosol outputs from nebulizers: application to World Health Organization measles aerosol project. Vaccine. 2008;26: 3534-3539.